SIMVASTATIN

Course overview

SIMVASTATIN IS AN ORAL HMG-COA REDUCTASE INHIBITOR INDICATED AS AN ADJUNCT TO DIET. IT IS A SEMI-SYNTHETIC DERIVATIVE OF LOVASTATIN, THE FIRST FDA-APPROVED STATIN. SIMVASTATIN HELPS LOWER CHOLESTEROL PRODUCTION AND REDUCE DYSLIPIDEMIA-ASSOCIATED COMPLICATIONS. HIGH CONCENTRATIONS OF LDL CHOLESTEROL CAN LEAD TO ARTERY DAMAGE, POTENTIALLY LEADING TO CARDIAC COMPLICATIONS AND STROKE. HOWEVER, THERE ARE SEVERAL MORE EFFECTIVE STATINS WITH MORE FAVORABLE ADVERSE EFFECT PROFILES. THIS ACTIVITY OUTLINES THE INDICATIONS, MECHANISM OF ACTION, METHODS OF ADMINISTRATION, SIGNIFICANT ADVERSE EFFECTS, CONTRAINDICATIONS, AND MONITORING, OF SIMVASTATIN, SO PROVIDERS CAN DIRECT PATIENT THERAPY IN TREATING HYPERLIPIDEMIA AS PART OF THE INTERPROFESSIONAL TEAM.